Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
Accession Number
DB00067  (BTD00110, BIOD00110, DB09392)
Small Molecule

Antidiuretic hormone, also known as vasopressin, is a nine amino acid peptide secreted from the posterior pituitary. Antidiuretic hormone binds to receptors in the distal or collecting tubules of the kidney and promotes reabsorbtion of water back into the circulation

  • Vasopressin, unspecified
  • Vasopressina
Product Ingredients
IngredientUNIICASInChI Key
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PitressinInjection20 [USP'U]/1mLIntramuscular; SubcutaneousPar Pharmaceutical2007-10-012016-06-30Us
PitressinInjection, solution20 [USP'U]/1mLIntramuscular; SubcutaneousPhysicians Total Care, Inc.2011-05-172011-09-30Us
PitressinInjection20 [USP'U]/1mLIntramuscular; SubcutaneousCardinal Health2007-10-012016-05-31Us
Pitressin Inj 10 Unit/0.5mlLiquidIntramuscular; SubcutaneousParke Davis Division, Warner Lambert Canada Inc.1971-12-311997-08-25Canada
Pressyn ArLiquidIntramuscular; SubcutaneousFerring Pharmaceuticals2002-11-042017-03-10Canada
VasopressinInjection, solution20 [USP'U]/1mLIntramuscular; SubcutaneousGeneral Injectables & Vaccines2010-03-012013-02-01Us
VasopressinInjection, solution20 [USP'U]/1mLIntramuscular; SubcutaneousGeneral Injectables & Vaccines2013-12-17Not applicableUs
VasopressinInjection, solution20 [USP'U]/1mLIntramuscular; SubcutaneousFresenius Kabi USA, LLC2001-07-17Not applicableUs
VasopressinInjection20 [USP'U]/1mLIntramuscularCardinal Health2011-10-172018-05-25Us
VasopressinInjection, solution20 [USP'U]/1mLIntramuscular; SubcutaneousGeneral Injectables & Vaccines2010-08-012013-03-01Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
PitressinVasopressin (20 [USP'U]/1mL)InjectionIntramuscular; SubcutaneousCardinal Health2007-10-012016-05-31Us
PitressinVasopressin (20 [USP'U]/1mL)InjectionIntramuscular; SubcutaneousPar Pharmaceutical2007-10-012016-06-30Us
PitressinVasopressin (20 [USP'U]/1mL)Injection, solutionIntramuscular; SubcutaneousPhysicians Total Care, Inc.2011-05-172011-09-30Us
VasopressinArgipressin (20 [USP'U]/1mL)Injection, solutionIntramuscular; SubcutaneousGeneral Injectables & Vaccines2010-03-012013-02-01Us
VasopressinVasopressin (20 [USP'U]/1mL)Injection, solutionIntramuscular; SubcutaneousGeneral Injectables & Vaccines2013-12-17Not applicableUs
VasopressinVasopressin (20 [USP'U]/1mL)InjectionIntramuscularCardinal Health2011-10-172018-05-25Us
VasopressinArgipressin (20 [USP'U]/1mL)Injection, solutionIntramuscular; SubcutaneousGeneral Injectables & Vaccines2010-08-012013-03-01Us
VasopressinArgipressin (20 [USP'U]/1mL)Injection, solutionIntramuscular; SubcutaneousAmerican Regent1992-10-012013-06-01Us
VasopressinArgipressin (20 [USP'U]/1mL)Injection, solutionIntravenous; SubcutaneousPhysicians Total Care, Inc.2011-05-172013-01-15Us
VasopressinArgipressin (20 [USP'U]/1mL)Injection, solutionIntramuscular; SubcutaneousAmerican Regent1992-10-012013-05-01Us
CAS number
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
Not Available
Not Available
Not Available



For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding

Associated Conditions

Vasopressin is an antidiuretic hormone indicated for the prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows, and in diabetes insipidus. Vasopressin can cause contraction of smooth muscle of the gastrointestinal tract and of all parts of the vascular bed, especially the capillaries, small arterioles and venules. It has less effect on the smooth musculature of the large veins. Vasopressin may also be used to control bleeding in some forms of von Willebrand disease and to treat extreme cases of bed wetting in children. It may also play a role in memory formation although the mechanism is unknown.

Mechanism of action

Vasopressin acts on three different receptors, vasopressin receptor V1a (which initiates vasoconstriction, liver gluconeogenesis, platelet aggregation and release of factor VIII), vasopressin receptor V1b (which mediates corticotrophin secretion from the pituitary) and vasopressin receptor V2 which controls free water reabsorption in the renal medullar. The binding of vasopressin to the V2 receptor activates adenylate cyclase which causes the release of aquaporin 2 channels into the cells lining the renal medullar duct. This allows water to be reabsorbed down an osmotic gradient so the urine is more concentrated.

AVasopressin V2 receptor
AVasopressin V1a receptorNot AvailableHumans
AVasopressin V1b receptorNot AvailableHumans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Not Available
Volume of distribution
Not Available
Protein binding



The majority of a dose of vasopressin is metabolized and rapidly destroyed in the liver and kidneys.

Route of elimination
Not Available
Half life

10-20 minutes

Not Available
Not Available
Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
ArdeparinThe therapeutic efficacy of Vasopressin can be decreased when used in combination with Ardeparin.
BemiparinThe therapeutic efficacy of Vasopressin can be decreased when used in combination with Bemiparin.
CarbamazepineThe risk or severity of water intoxication can be increased when Carbamazepine is combined with Vasopressin.
CertoparinThe therapeutic efficacy of Vasopressin can be decreased when used in combination with Certoparin.
DalteparinThe therapeutic efficacy of Vasopressin can be decreased when used in combination with Dalteparin.
DanaparoidThe therapeutic efficacy of Vasopressin can be decreased when used in combination with Danaparoid.
EnoxaparinThe therapeutic efficacy of Vasopressin can be decreased when used in combination with Enoxaparin.
HeparinThe therapeutic efficacy of Vasopressin can be decreased when used in combination with Heparin.
LevothyroxineLevothyroxine may increase the vasoconstricting activities of Vasopressin.
LidocaineThe risk or severity of hypertension can be increased when Vasopressin is combined with Lidocaine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Ethanol


Synthesis Reference

Nedumparambil A. Abraham, Hans U. Immer, Kazimir Sestanj, "Process for producing triglycyl-lysine vasopressin and intermediates therefor." U.S. Patent US4093610, issued June, 1963.

General References
  1. Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ: Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology. 2004 Mar;29(3):483-93. [PubMed:14647484]
  2. Wersinger SR, Caldwell HK, Martinez L, Gold P, Hu SB, Young WS 3rd: Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression. Genes Brain Behav. 2007 Aug;6(6):540-51. Epub 2006 Nov 3. [PubMed:17083331]
  3. Lolait SJ, Stewart LQ, Jessop DS, Young WS 3rd, O'Carroll AM: The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology. 2007 Feb;148(2):849-56. Epub 2006 Nov 22. [PubMed:17122081]
  4. Wersinger SR, Kelliher KR, Zufall F, Lolait SJ, O'Carroll AM, Young WS 3rd: Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task. Horm Behav. 2004 Dec;46(5):638-45. [PubMed:15555506]
  5. Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, Kubes P: Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood. 1995 Oct 1;86(7):2760-6. [PubMed:7545469]
External Links
KEGG Compound
PubChem Substance
Therapeutic Targets Database
RxList Drug Page Drug Page
AHFS Codes
  • 68:28.00 — Pituitary
Download (143 KB)

Clinical Trials

Clinical Trials
0CompletedBasic ScienceHepatic Hemodynamics / Liver Surgery / Portal Blood Pressure1
0CompletedBasic SciencePsychology, Social2
0TerminatedTreatmentTraumatic Injuries / Traumatic Shock1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedDiagnosticAutism Spectrum Conditions/Disorders1
1CompletedTreatmentCardiac Arrest / Cardio Respiratory Arrest1
1RecruitingTreatmentAbortion Early / Abortion in First Trimester / Missed Abortion / Spontaneous Abortions1
1RecruitingTreatmentHealthy Volunteer Safety Study1
1, 2RecruitingBasic ScienceADH / Analgesia / Antidiuretic Hormone / Arginine Vasopressin / Placebo / Social Behavior1
2CompletedTreatmentAcute Lung Injury (ALI)1
2CompletedTreatmentAutism Spectrum Conditions/Disorders1
2CompletedTreatmentChronic Heart Failure (CHF)1
2CompletedTreatmentEnd Stage Renal Disease (ESRD) / High Blood Pressure (Hypertension)1
2CompletedTreatmentHeart Arrest1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentShock, Septic1
2CompletedTreatmentTraumatic Shock1
2RecruitingTreatmentASD / Autism Spectrum Conditions/Disorders / Autism, Early Infantile1
2RecruitingTreatmentOut-Of-Hospital Cardiac Arrest1
2TerminatedTreatmentPulmonary Hypertension (PH)1
2, 3CompletedTreatmentHypovolaemia / Shock / Shock, Hemorrhagic1
2, 3CompletedTreatmentSepsis / Shock, Septic1
2, 3CompletedTreatmentShock, Septic1
2, 3CompletedTreatmentSubmucous Leiomyoma of Uterus1
2, 3Not Yet RecruitingTreatmentCirculatory collapse and shock / Non-cardiac Surgery1
2, 3RecruitingTreatmentCirculatory Perfusion Disorder / Congenital Heart Disease (CHD) / Single-ventricle1
2, 3RecruitingTreatmentHeart Arrest1
2, 3SuspendedTreatmentPleural Effusions / Single-ventricle1
3CompletedTreatmentCardiac Arrest2
3CompletedTreatmentShock, Septic1
3CompletedTreatmentUterine Leiomyomas1
3Unknown StatusTreatmentShock1
4CompletedBasic ScienceEndotoxaemia1
4CompletedPreventionRenal Failure1
4CompletedTreatmentBlood Loss During Vaginal Hysterectomy1
4CompletedTreatmentBlood Loss,Surgical1
4CompletedTreatmentCardiac Arrest1
4RecruitingTreatmentCardiac Arrest1
4WithdrawnTreatmentShock, Septic1
Not AvailableCompletedNot AvailableDetermine if Sweat [Na+] is Regulated by the V2R / Electrolyte imbalance / Hypernatremia / Hyponatremia1
Not AvailableCompletedNot AvailableRotator Cuff Tear Arthropathy1
Not AvailableCompletedBasic ScienceHealthy Volunteers2
Not AvailableCompletedDiagnosticShock, Septic1
Not AvailableCompletedOtherSchizophrenia1
Not AvailableCompletedPreventionHypotension1
Not AvailableCompletedTreatmentHepatic Failure1
Not AvailableCompletedTreatmentHypotension1
Not AvailableCompletedTreatmentHypotension / Shock1
Not AvailableCompletedTreatmentPain / Pregnancy Termination1
Not AvailableCompletedTreatmentTraumatic Brain Injury (TBI)1
Not AvailableNot Yet RecruitingNot AvailableCardiac Arrest1
Not AvailableNot Yet RecruitingBasic ScienceHealthy Volunteers1
Not AvailableNot Yet RecruitingPreventionBenign muscle neoplasm1
Not AvailableNot Yet RecruitingTreatmentCerebral Oxygen Saturation1
Not AvailableRecruitingPreventionBenign muscle neoplasm1
Not AvailableRecruitingPreventionBurn Surgery / Use of Vasopressin in Burn Surgery1
Not AvailableRecruitingPreventionPlacenta Previa1
Not AvailableRecruitingTreatmentHigh Blood Pressure (Hypertension)1
Not AvailableTerminatedSupportive CareShock, Septic1
Not AvailableUnknown StatusBasic ScienceHealthy Volunteers1


  • Parke davis div warner lambert co
  • American Regent
  • APP Pharmaceuticals
  • APPD
  • A-S Medication Solutions LLC
  • Cardinal Health
  • JHP Pharmaceuticals LLC
  • Luitpold Pharmaceuticals Inc.
  • Monarch Pharmacy
  • PD-Rx Pharmaceuticals Inc.
Dosage forms
InjectionIntramuscular; Subcutaneous20 [USP'U]/1mL
Injection, solutionIntramuscular; Subcutaneous20 [USP'U]/1mL
LiquidIntramuscular; Subcutaneous
InjectionIntramuscular20 [USP'U]/1mL
Injection, solutionIntravenous; Subcutaneous20 [USP'U]/1mL
LiquidIntramuscular; Nasal; Subcutaneous
SolutionIntramuscular; Subcutaneous
InjectionIntravenous20 [USP'U]/1mL
Unit descriptionCostUnit
Pitressin 20 unit/ml vial7.68USD ml
Vasopressin 10 unit/0.5 ml vial2.88USD vial
Vasopressin 20 unit/ml vial1.86USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more


Experimental Properties
water solubilitySolubleNot Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available


Mass Spec (NIST)
Not Available
Not Available


Not classified


Pharmacological action
General Function
Vasopressin receptor activity
Specific Function
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
Gene Name
Uniprot ID
Uniprot Name
Vasopressin V2 receptor
Molecular Weight
40278.57 Da
  1. Boson WL, Della Manna T, Damiani D, Miranda DM, Gadelha MR, Liberman B, Correa H, Romano-Silva MA, Friedman E, Silva FF, Ribeiro PA, De Marco L: Novel vasopressin type 2 (AVPR2) gene mutations in Brazilian nephrogenic diabetes insipidus patients. Genet Test. 2006 Fall;10(3):157-62. [PubMed:17020465]
  2. Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. [PubMed:16333859]
  3. Bouley R, Hawthorn G, Russo LM, Lin HY, Ausiello DA, Brown D: Aquaporin 2 (AQP2) and vasopressin type 2 receptor (V2R) endocytosis in kidney epithelial cells: AQP2 is located in 'endocytosis-resistant' membrane domains after vasopressin treatment. Biol Cell. 2006 Apr;98(4):215-32. [PubMed:16563128]
  4. Yi X, Bouley R, Lin HY, Bechoua S, Sun TX, Del Re E, Shioda T, Raychowdhury MK, Lu HA, Abou-Samra AB, Brown D, Ausiello DA: Alix (AIP1) is a vasopressin receptor (V2R)-interacting protein that increases lysosomal degradation of the V2R. Am J Physiol Renal Physiol. 2007 May;292(5):F1303-13. Epub 2007 Feb 6. [PubMed:17287200]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Pharmacological action
General Function
Vasopressin receptor activity
Specific Function
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behavi...
Gene Name
Uniprot ID
Uniprot Name
Vasopressin V1a receptor
Molecular Weight
46799.105 Da
  1. Hiroyama M, Wang S, Aoyagi T, Oikawa R, Sanbe A, Takeo S, Tanoue A: Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice. Eur J Pharmacol. 2007 Mar 22;559(2-3):89-97. Epub 2006 Dec 29. [PubMed:17275806]
  2. Liedman R, Grant L, Igidbashian S, James I, McLeod A, Skillern L, Akerlund M: Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea. Acta Obstet Gynecol Scand. 2006;85(2):207-11. [PubMed:16532916]
  3. Adikesavan NV, Mahmood SS, Stanley N, Xu Z, Wu N, Thibonnier M, Shoham M: A C-terminal segment of the V1R vasopressin receptor is unstructured in the crystal structure of its chimera with the maltose-binding protein. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Apr 1;61(Pt 4):341-5. Epub 2005 Mar 24. [PubMed:16511036]
  4. Hammock EA, Lim MM, Nair HP, Young LJ: Association of vasopressin 1a receptor levels with a regulatory microsatellite and behavior. Genes Brain Behav. 2005 Jul;4(5):289-301. [PubMed:16011575]
  5. Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A: Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007 May;148(5):2075-84. Epub 2007 Feb 15. [PubMed:17303660]
Pharmacological action
General Function
Vasopressin receptor activity
Specific Function
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.
Gene Name
Uniprot ID
Uniprot Name
Vasopressin V1b receptor
Molecular Weight
46970.345 Da
  1. Young WS, Li J, Wersinger SR, Palkovits M: The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience. 2006 Dec 28;143(4):1031-9. Epub 2006 Oct 4. [PubMed:17027167]
  2. Volpi S, Liu Y, Aguilera G: Vasopressin increases GAGA binding activity to the V1b receptor promoter through transactivation of the MAP kinase pathway. J Mol Endocrinol. 2006 Jun;36(3):581-90. [PubMed:16720725]
  3. Wersinger SR, Caldwell HK, Christiansen M, Young WS 3rd: Disruption of the vasopressin 1b receptor gene impairs the attack component of aggressive behavior in mice. Genes Brain Behav. 2007 Oct;6(7):653-60. Epub 2006 Dec 20. [PubMed:17284170]
  4. Slusarz MJ, Gieldon A, Slusarz R, Ciarkowski J: Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems. J Pept Sci. 2006 Mar;12(3):180-9. [PubMed:16114100]
  5. Jurkevich A, Berghman LR, Cornett LE, Kuenzel WJ: Characterization and immunohistochemical visualization of the vasotocin VT2 receptor in the pituitary gland of the chicken, Gallus gallus. Gen Comp Endocrinol. 2005 Aug;143(1):82-91. Epub 2005 Mar 23. [PubMed:15993108]


Pharmacological action
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
Uniprot ID
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
  1. Madon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B: Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000 Mar;57(3):634-41. [PubMed:10692506]

Drug created on June 13, 2005 07:24 / Updated on January 19, 2020 15:44